Table 4.
Comparative characteristics of COVID-19 vaccine-related headache and primary headache disorders in the healthcare workers.
| (1)COVID-19 vaccine-related headachen = 556 | (2)Migraine(definite or probable)n = 446 | (3)TTH(definite orprobable)n=357 | p (1 vs. 2)* | p (1 vs. 3)* | |
|---|---|---|---|---|---|
| Headache location | |||||
| Unilateral/more prominent on one side n (%) | 184 (33.1) | 305 (68.4) | 141 (39.5) | <0.001 | 0.06 |
| Bilateral n (%) | 372 (66.9) | 141 (31.6) | 216 (60.5) | ||
| Accompanying symptoms | |||||
| Aggravation with physical activity n (%) | 137 (24.6) | 366 (82.1) | 170 (47.6) | <0.001 | <0.001 |
| Phonophobia n (%) | 83 (14.9) | 307 (68.3) | 72 (20.2) | <0.001 | 0.05 |
| Photophobia n (%) | 94 (16.9) | 335 (75.21) | 43 (12) | <0.001 | 0.05 |
| Nausea n (%) | 67 (12.1) | 266 (59.6) | 11 (3.1) | <0.001 | <0.001 |
| Osmophobia n (%) | 22 (4) | 119 (26.7) | 8 (2.2) | <0.001 | 0.2 |
| None n (%) | 198 (35.61) | 20 (4.5) | 242 (67.8) | <0.001 | <0.001 |
| Severity of headache | |||||
| Mild n (%) | 126 (22.7) | 26 (5.8) | 77 (21.6) | <0.001 | <0.001 |
| Moderate n (%) | 370 (66.5) | 326 (73.1) | 271 (75.9) | ||
| Severe n (%) | 60 (10.79) | 94 (21.1) | 9 (2.5) | ||
| Duration of headache, days | |||||
| Median (IQR) | 0.5 (0.2–3) | 0.3 (0.2–0.7) | 0.2 (0.1–0.3) | <0.001 | <0.001 |
Note: Numbers in bold are statistically significant values.TTH: Tension type headache.
*Mann-Whitney U or Pearson Chi-square.
IQR, Interquartile range (Q1–Q3)